Sunday, May 25, 2014

IPF Clinical Trials Webinar, May 28, 2014, 1pm Central Time

The Pulmonary Fibrosis Foundation is holding a free webinar at 1pm CT on May 28, 2014 to provide information about the results of the three recent IPF clinical trials. I will be participating in the webinar, along with Greg Cosgrove, MD and Kevin Flaherty, MD. You can learn more and register here.

Here is the PFF's full press release:

Results from Boehringer Ingelheim, InterMune and IPFnet clinical trials discussed

WHO: The Pulmonary Fibrosis Foundation (PFF) will discuss results from recent idiopathic pulmonary fibrosis (IPF) clinical trials in an upcoming webinar.  Boehringer Ingelheim and InterMune both recently released data from their Phase III randomized, placebo-controlled trials, each demonstrating efficacy for those living with IPF. Also results from the IPFnet N-Acetylcysteine (NAC) randomized trial will be presented.

WHO SHOULD PARTICIPATE: Anyone interested in learning about the results from these important clinical trials and what effect they will have on the pulmonary fibrosis (PF) community. Viewers will be able to submit questions to our medical experts.

WHAT: Pulmonary Fibrosis Foundation webinar “Ask a Doc: Clinical Trial Update” in which Dr. Gregory P. Cosgrove, Dr. Kevin R. Flaherty and Dr. David J. Lederer will explain the findings of recent clinical trials presented at the ATS meeting, and they will also answer questions from the viewers.

“The PF community has struggled to find successful treatments for those impacted by this disease,” said Daniel M. Rose, MD, Chief Executive Officer and PFF Chairman of the Board. “This is a significant day for the PF community because after years of few therapeutic options, patients with IPF will finally have some choices.”

Boehringer Ingelheim released the results from their INPULSIS trials examining the safety and efficacy of nintedanib in patients with IPF. The primary endpoint in these trials, the annual rate of decline in forced vital capacity (FVC), was significantly reduced, indicating the rate of disease progression in the group receiving nintedanib was slower than those taking placebo.

InterMune released results from the ASCEND trial confirming that pirfenidone has an effect on disease progression in patients with IPF. This 52-week trial showed a statistically significant reduction in the rate of decline in FVC in those receiving pirfenidone versus those receiving placebo. This indicates that pirfenidone is effective in slowing disease progression in patients with IPF. Based on this data, InterMune has communicated its intent to resubmit a New Drug Application to the U.S. Food and Drug Administration to seek approval of pirfenidone to treat individuals with mild-to-moderate IPF.

WHEN: May 28, 2014, 1:00 p.m. Central

WHERE: To register, please visit

Michelle Michael
VP, Marketing & Communications


  1. Dr. Lederer will this be rebroadcast? I will be in the middle of clinical trial infusion and do not want to miss this webcast.

    1. I suspect the PFF will make the webinar available on their website for viewing.

  2. They've indicated about one week to post the recorded webinar. I expect the recorded webinars will be found at We're still waiting for the May 21st webinar to be posted but then it hasn't been a week yet -- maybe Wednesday or Thursday.


    May 14, 2014 webinar recording has been posted today for those who missed it or simply want to review it.

    "What is Pulmonary Fibrosis?" s

  4. You can now watch this webinar and/or download the slides. s/ask-a-doc-clinical-trial-update